4-(1-(2-(3-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)quinolin-6-yl)ethyl)-6-oxo-1,6-dihydropyridazin-3-yl)-N-methyl-2-(trifluoromethyl)benzamide

ID: ALA5170338

Chembl Id: CHEMBL5170338

PubChem CID: 168270117

Max Phase: Preclinical

Molecular Formula: C29H25F3N6O3

Molecular Weight: 562.55

Associated Items:

Names and Identifiers

Canonical SMILES:  CNC(=O)c1ccc(-c2ccc(=O)n(CCc3ccc4ncc(-c5cnn(CCO)c5)cc4c3)n2)cc1C(F)(F)F

Standard InChI:  InChI=1S/C29H25F3N6O3/c1-33-28(41)23-4-3-19(14-24(23)29(30,31)32)26-6-7-27(40)38(36-26)9-8-18-2-5-25-20(12-18)13-21(15-34-25)22-16-35-37(17-22)10-11-39/h2-7,12-17,39H,8-11H2,1H3,(H,33,41)

Standard InChI Key:  FLGNFHLYCVKCPR-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA5170338

    ---

Associated Targets(Human)

MET Tclin Hepatocyte growth factor receptor (10718 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Hs746T (53 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 562.55Molecular Weight (Monoisotopic): 562.1940AlogP: 3.94#Rotatable Bonds: 8
Polar Surface Area: 114.93Molecular Species: NEUTRALHBA: 8HBD: 2
#RO5 Violations: 1HBA (Lipinski): 9HBD (Lipinski): 2#RO5 Violations (Lipinski): 1
CX Acidic pKa: 13.74CX Basic pKa: 3.85CX LogP: 3.09CX LogD: 3.09
Aromatic Rings: 5Heavy Atoms: 41QED Weighted: 0.30Np Likeness Score: -1.63

References

1. Wang C, Li J, Qu L, Tang X, Song X, Yang F, Chen X, Lin Q, Lin W, Zhou Y, Tu Z, Chen Y, Zhang Z, Lu X..  (2022)  Discovery of D6808, a Highly Selective and Potent Macrocyclic c-Met Inhibitor for Gastric Cancer Harboring MET Gene Alteration Treatment.,  65  (22.0): [PMID:36355693] [10.1021/acs.jmedchem.2c00981]

Source